This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

ZERO's CEO Steps Down After Thirteen Years Of Leadership

WASHINGTON, March 26, 2013 /PRNewswire-USNewswire/ -- Quentin "Skip" Lockwood, III, President and Chief Executive Officer of ZERO – The End of Prostate Cancer has resigned his position in order to pursue a new opportunity at a family business in upstate New York. Skip lent his leadership skills to the organization for thirteen years, serving five of those as CEO.


"The Board would like to thank Skip for his incredible service and accomplishments with ZERO," said Jonathan Schwartz, Chairman of the Board of Directors at ZERO. "We are sad to see him go and wish him nothing but good fortune in his new endeavor."  

Skip worked tirelessly for the past thirteen years to achieve his vision of Generation ZERO – the first generation of men free from prostate cancer. His legacy includes increasing the organization's operating budget from $1.3 million to $3.8 million, forging relationships with high profile organizations and celebrities to increase prostate cancer awareness, and educating countless men about the disease through ZERO's many programs and events.

During his time at ZERO, Skip was instrumental in bringing the Drive Against Prostate Cancer, a mobile education and cancer testing program, to the organization. The Drive, now known as ZERO Prostate Cancer Testing, has alerted more than 120,000 men to potentially live-saving information and educated countless others.

ZERO Prostate Cancer Challenge (ZPCC), now the largest men's health event series in the nation, was formed under Skip's leadership. Comprised of run/walks, golf tournaments and teams at top endurance events, ZPCC events are hosted by urology practices and oncology centers in more than 60 locations across the nation, bringing together athletes, cancer patients and survivors, physicians, caretakers, family members and friends in the fight to end prostate cancer.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,776.43 +304.06 1.85%
S&P 500 1,987.05 +35.69 1.83%
NASDAQ 4,781.2640 +73.4890 1.56%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs